Loading
SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.59, clinical 0.90).
In plain words · SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase.
No product in this corpus aims at SSTR4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA not detected, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SSTR4: RNA not detected; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); Open Targets associates it with 1 specific cancer type at or above 0.5 (carcinoid tumor). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SSTR4 tissue; Open Targets ENSG00000132671 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Xu et al, Biochem. Biophys. Res. Commun, 1993, "Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4". Source.
Sources: HGNC HGNC:11333 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31391 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000132671 (association with cancer (MONDO_0004992) 0.57; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.59 (GraphQL API, CC0))
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. Mediates antiproliferative action of somatostatin in tumour cells. Location: Cell membrane (UniProt). Locus 20p11.21 (HGNC).
RNA: not detected, not detected normal tissues.
No normal tissue stained high.
No cancer stained high; medium in lung cancer, pancreatic cancer.
HPA SSTR4 tissue · HPA SSTR4 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SSTR4" OR ABSTRACT:"SSTR4" OR TITLE:"somatostatin receptor 4" OR ABSTRACT:"somatostatin receptor 4" OR TITLE:"Somatostatin receptor type 4" OR ABSTRACT:"Somatostatin receptor type 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSTR4, not a curated reading list.